New research reveals that patients who discontinue popular slimming jabs like semaglutide or tirzepatide may regain shed pounds much more quickly than those who halt conventional diet and exercise programs.
Research printed in a major health publication points out that while overweight individuals often shed a large proportion of their total mass while undergoing treatment, the weight returns at an average rate of 0.8 kg per month once they quit.
"People using such medications should be aware of the danger of fast rebound weight gain when the treatment concludes," warns lead investigator Dr. Susan Jebb.
This pace of recovery implies a reversion to starting weight within about a year and a half.
Comparing Treatments
The research, which looked at 37 of trials involving thousands of patients, compared the effects of GLP-1 agonists with older methods.
Scientists point out that individuals who shed pounds through lifestyle changes alone usually have a more gradual creep back—approximately 0.1 kg a month—once they finish.
Understanding the Quick Regain
Doctors believe the mechanism of the jabs explains the heightened regain.
These medications copy a natural hormone called GLP-1, which moderates appetite.
"Long-term administration of GLP-1 levels far above than the body's typical production may cause the body to generate a reduced amount of its own natural hormone, and may also diminish sensitivity to its effects," said Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this GLP-1 'fix' means appetite is no longer kept in check, making overeating far more likely."
A Chronic Condition?
Health authorities advise the jabs for individuals with weight-linked health risks, alongside recommended diet and exercise modifications.
A number of clinicians say that, given the high risk of relapse, the therapy might need to be long-term.
This perspective is reinforced by pharmaceutical companies, who state that the results "highlight the chronic character of excess weight," similar to managing diseases like diabetes.
User Testimonies
Individuals who have come off the medication describe a sudden resurgence of appetite.
"It was like a trigger that goes on and you become starving," recalled a patient.
This challenge is compounded if patients have not adopted sustainable lifestyle or habit modifications during therapy.
Significant Use
Figures show that millions of people in the UK have tried weight-loss jabs in the past year, with interest continuing to grow.
- Use is more common among females than males.
- The middle-aged demographic shows the highest usage rates.
- Many access the medications through private healthcare rather than public health services.
Finally, clinicians emphasize that while the jabs are effective agents for shedding pounds, they are not a standalone solution and long-term success hinges on combined behavioural support.
